TrialJID innovations : skin science from molecules to population health2025

Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study.

Caroline J Stone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.